CHAPTER 10

Multi-functional Hemoglobin Dehaloperoxidases

STEFAN FRANZEN,*[a] REZA A. GHILADI,[a] LUKASZ LEBIODA[b] AND JOHN DAWSON[b]

[a] Department of Chemistry, North Carolina State University, Raleigh, NC, US; [b] Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC, US
*Email: Stefan_Franzen@ncsu.edu

10.1   Introduction

The peroxidase family is characterized by an α-helical fold, a mechanism that involves activation of bound H_2O_2, and substrate binding to permit electron transfer from the substrate to the heme. Cytochrome c peroxidase (CcP), the prototypical member of the peroxidase superfamily, has the α-helical fold common to many of the peroxidases described previously in this book. The hemoglobin family has a different α-helical fold, which is conserved across a vast number of organisms.[1] Hemoglobins lack the crucial conserved amino acids of the CcP family that are relevant for catalysis and consequently are poor peroxidases. Nonetheless, the hemoglobin gene is thought to be the oldest heme protein gene and it is therefore possible that hemoglobins have had peroxidase activity at some point in evolution. Given the prevalence of hemoglobins, it is therefore possible that some hemoglobins in modern ecosystems have peroxidase activity either preserved as one branch of the divergent evolution of globins, or perhaps as a result of convergent evolution in response to the particular evolutionary pressure of an ecosystem. These issues have become sufficiently compelling because

of the discovery of the hemoglobin-dehaloperoxidase (DHP)[2] from *Amphitrite ornata* that possesses both oxygen-transport and peroxidase activities. This chapter will be devoted to a comparison of the similarities and differences between DHP and the C*c*P family. Although DHP serves a singular example, it is believed that DHP represents a possible set of mechanisms in globins that may be found in other organisms as well.

10.1.1 Physiological Roles of DHP

The discovery of peroxidase activity in a hemoglobin is not a complete surprise. Since the work of George and Irvine in 1951,[3–5] it has been known that hemoglobins have some peroxidase activity,[6–9] most often manifesting under pathological (post-hemolytic) conditions. The idea of engineering a peroxidase function into a myoglobin has resulted in several successful examples of mutant globins with modest peroxidase activity.[10–12] However, for the most part hemoglobins are poor peroxidases as the erythrocyte/myocyte actively suppresses their inherent peroxidase activity.[13] The evolved hemoglobins in higher life forms do not require peroxidase activity and, indeed, there is a conflict between H_2O_2-binding and activation with the binding and transport of oxygen. These studies cause us to ask: "When is peroxidase activity truly important for physiology?" This chapter will reveal highly specific aspects of the mechanism and interactions of both substrates and hydrogen peroxide with DHP that clearly show that peroxidase activity is not an artifact in this case.

The consideration of the environmental factors and complex interactions of a number of molecules with DHP suggest that there is an evolutionary pressure on DHP that is consistent with its current place as the best peroxidase of any known globin. *A. ornata* is a worm found in relatively shallow muddy coastal waters and marine estuaries. There are many life forms in these ecosystems that produce toxic brominated and chlorinated compounds.[14–17] Such compounds are repellents that offer protection against predators and may have other functions in preventing attack by fungi or microorganisms. In North Carolina, some of the coastal regions have such a high load of these odiferous brominated compounds that they are called "bromine flats". A number of species in these ecosystems produce brominated phenols, pyrroles and indoles as the most common compounds. Our hypothesis is that DHP has evolved to degrade a number of these compounds, which are produced by other organisms and indeed by related heme proteins.[18] DHP is a sufficiently active peroxidase that it was originally named "dehaloperoxidase" when it was discovered in 1996 as the fraction from *A. ornata* that was capable of degrading the known marine toxin 2,4,6-tribromophenol.[2] It is remarkable that DHP was known previously as a hemoglobin, and was characterized first as such in 1977 by Bonaventura *et al.*[19] The fact that DHP is a globin became obvious when the DHP structure and amino acid sequence were determined.[20,21] Given what is known about the role played by *A. ornata* in benthic ecosystems, DHP may well be

one of the few proteins capable of protecting the worm (technically a ter-
ebellid polychaete) against the onslaught of the toxic compounds produced
by many of its neighbors.[14,15,22,23] Given this history and dual roles in bio-
logical function, the name hemoglobin-dehaloperoxidase will be used in this
chapter in addition to the more commonly used shorthand notation of
dehaloperoxidase (or DHP).

10.1.2 The Two Isoforms of DHP

There are two isoforms of DHP, known as A and B.[22] The reactivity of DHP A
as a peroxidase was shown first in 1996.[2,24] In 2010, recombinant DHP B was
created by mutation of the five amino acids that differ from DHP A.[25,26] DHP
B has four times higher peroxidase activity than DHP A for 2,4,6-tri-
bromophenol, which makes this isoform the naturally occurring hemoglobin
with greatest known peroxidase activity. DHP is the most abundant protein in
A. ornata and is responsible for the reddish color of the organism; however, it
is not known what DHP percentage is produced in each isoform, if their
expression is environmentally controlled, and how their concentrations
and distribution compares to the erythrocruorins. The available evidence
suggests DHP A is the dominant form in DHP isolates from *A. ornata*.[21] The
isoforms are of particular interest mainly because they are examples of multi-
functional proteins that permit one to begin to study the structural origins of
the unique reactivity of this small protein. There are two forms of hemoglobin
in the organism: DHP that is found in the coelom (space between the outer
wall of the worm and its feeding tube), and a giant hemoglobin that is found
in the tentacles. The oxygen affinities: 4.2 torr for DHP A, 2.0 torr for DHP B[27]
and 11 torr for giant hemoglobin[19] suggest that the worm tentacles absorb
oxygen with the giant hemoglobin (or erythrocruorin), which is then trans-
ferred to DHP for storage and release in the main body.[28,29] Unlike the giant
Hb, DHP is a monomeric intracellular protein.[19] There is some tendency for
DHP to dimerize *in vitro*[30] but since its intracellular concentration is not
known, the DHP physiological state is uncertain. The dimer interface ob-
served in DHP crystals is different from those in mammalian hemoglobins.[21]
Nonetheless, DHP A and B may be constituents of the erythrocruorin since
there are only two hemoglobin genes identified in *A. ornata*.[22]

   While this chapter will focus mainly on the dehaloperoxidase activity of
DHP, the multi-functional nature of the protein is noteworthy. It has recently
been shown that DHP can support both peroxygenase and oxidase mech-
anisms for certain substrates.[31] DHP is also known as an excellent sulfide
oxidase,[32] which is yet another function related to the proposed protective
function. The available structural evidence suggests that there are at least
three binding sites (two internal and one external) that can account for this
variety of mechanisms and specific inhibition. While the multi-functional
nature of DHP is of great interest, this chapter will focus specifically on
a comparison of the peroxidase activity in DHP with that in prototypical
peroxidases, such as horseradish peroxidase (HRP).

10.2 Peroxidase Mechanism of DHP

10.2.1 DHP Mechanism Initiated from the Ferric State

Both isoenzymes of DHP (A and B) catalyze the oxidative degradation of 2,4,6-trihalogenated phenols (substrate) to the corresponding 2,6-dihalo-1,4-benzo-quinones in the presence of H_2O_2. Several recent studies have focused on the characterization of DHP, as well as elucidating the mechanism of this reaction when starting from the ferric resting state. In the absence of a reducing substrate, DHP initially reacts with H_2O_2 to generate Compound I, which rapidly converts (<1 ms) to an iron(IV)-oxo heme center with a tyrosyl radical that has been termed Compound ES by analogy with cytochrome *c* peroxidase (Figure 10.1). The role(s) for the radical(s) in Compound ES with respect to protecting the enzyme against heme bleaching is discussed in a later section. The catalytic competency of both Compound I and Compound ES intermediates in oxidizing the substrate 2,4,6-tricholorophenol (TCP) to 2,4-dichloroquinone (DCQ) has been shown. As discussed in a later section, it has also been found that in the absence of substrate, there is the formation of a new species named Compound RH,[33] which is unique to dehaloperoxidase and has not been found in any other globin. This species is thought to protect the enzyme from oxidative damage and irreversible inactivation under conditions of low substrate concentration. The turnover of TCP by horseradish peroxidase (HRP) and *C. fumago* chloroperoxidase have been studied previously.[34,35] While both are more rapid than DHP A by a factor of $\sim$12, the catalytic activity of DHP A is at least 10 times greater than that of SWMb.[36,37] DHP B is $\sim$4.3-fold more active than DHP A, so that it is within a


Figure 10.1 Mechanism for trihalophenol (TXP) oxidation by ferric DHP utilizing H_2O_2 as the oxidant.

factor of 3 of HRP activity.[25,38] The dehaloperoxidase activity of DHP has also been reported to be greater using *meta*-chloroperoxybenzoic acid in place of hydrogen peroxidase as the oxygen donor to initiate the reaction.[39]

The evidence strongly suggests an overall two-electron oxidation of TCP by DHP that proceeds through discrete one-electron steps. The product DCQ itself is not an innocent species, having been shown to react separately with both Compound ES and ferric DHP to yield oxyferrous DHP in either case.[25,33] The unusually high reduction potential for DHP (when compared with other peroxidases) of $\sim +205$ mV reported for DHP likely facilitates reactions with DCQ that ultimately favor the reduction of the heme prosthetic group and formation of oxyferrous DHP.[40] Thus, DCQ chemistry may represent one possible link between the two namesake activities of hemoglobin-dehaloperoxidase by allowing for the ferric state to either initiate a peroxidase pathway in the presence of TCP and H_2O_2, or form the oxyferrous complex in the presence of DCQ (itself generated from the aforementioned peroxidase pathway) and thus enabling the O_2-transport function.

10.2.2 DHP Mechanism Initiated from the Ferrous State

While progress has been made toward understanding the DCQ-driven functional switch of how the peroxidase-active ferric DHP state can be converted to the oxygen-binding ferrous form, the reverse, wherein oxyferrous DHP is activated toward peroxidase function, is more controversial. Given that reversible oxygen-binding is only mediated *via* a ferrous heme in globins, and that peroxidase activity is initiated from ferric centers and to the exclusion of the oxyferrous oxidation state from the peroxidase cycle, the bifunctional nature of DHP as a globin-peroxidase appears to be at odds with the traditional starting oxidation state for each individual activity—this has been referred to as "the dehaloperoxidase paradox".[41] In a peroxidase reaction that is unique to DHP, it has recently been reported that dehaloperoxidase activity has been observed when the catalytic cycle is initiated from the oxyferrous state, but that the catalytically active species is only formed in the presence of the TCP substrate.[42] The lack of reactivity observed for oxyferrous DHP when trihalophenol substrate was absent may have a physiological role, preventing formation of Compound RH (with its attenuated dehaloperoxidase activity) when exposed to hydrogen peroxide for short reaction times (<60 s), and also minimizing the deleterious effects of unwanted peroxidase activity in the absence of a reducing substrate. These observations suggest that the involvement of substrate is the key factor in the functional switch of DHP from that of an oxygen-binding protein to a peroxidase. The two current hypotheses for how trihalophenol substrate is involved in the activation of oxyferrous DHP for peroxidase function are:

(i) TCP radicals (TCP$^\bullet$), themselves formed from trace amounts of the ferric enzyme reacting with TCP and hydrogen peroxide, oxidize oxyferrous DHP to the peroxidase active ferric form. This radical-based

activation mechanism has precedent with the mono-functional lignin peroxidase (LiP), where veratryl alcohol oxidation has been shown to yield radical species that oxidize oxy-LiP to the peroxidase-active ferric enzyme. Evidence in support of this substrate radical-based activation include: (a) the lag time seen of the dehaloperoxidase activity when turnover is initiated by H_2O_2 addition to the TCP-bound oxyferrous enzyme is sensitive to both TCP and H_2O_2 concentration showing that both substrate and H_2O_2 are necessary to convert the enzyme to the catalytically active state. The lag time also is decreased when a small amount of ferric DHP is added to oxyferrous DHP to purposefully generate TCP$^\bullet$ following addition of H_2O_2.[43] (b) In the presence of excess TCP, one equivalent of H_2O_2 (or even as little as 0.5 equiv) converts oxyferrous DHP to the catalytically active ferric state.[43] (c) Ferrocyanide, a known peroxidase substrate with a structure that is completely different from TCP, also triggers the functional switch of oxyferrous DHP to catalytically active enzyme showing that an inorganic one-electron redox agent can take the place of the TCP$^\bullet$ in promoting the switch.[44] (d) Ferric heme iron ligands such as imidazole and cyanide and organic radical traps such as 5,5-dimethyl-1-pyrroline-*N*-oxide (DMPO) effectively inhibit the TCP-based switch, although DMPO does not inhibit the ferrocyanide-based switch which does not involve organic radicals.[44] Taken together, these data support a mechanism for the activation of oxyferrous DHP in which trace amounts of the ferric enzyme present in the oxyferrous protein catalyze formation of TCP$^\bullet$ which oxidizes deoxyferrous DHP to the catalytically active ferric state.

(ii) Substrate binding to DHP destabilizes the oxyferrous state in the presence of hydrogen peroxide, leading to a reaction between ferrous DHP and H_2O_2.[42] Evidence in support of this ferrous DHP based reaction include: (a) anaerobic studies on the reaction of deoxyferrous DHP with H_2O_2 yielded Compound II, one of the active species of the peroxidase cycle, and did not require substrate to be present. The conversion of deoxyferrous hemoproteins to Compound II has been noted and/or postulated in a number of other systems, including horseradish peroxidase, leghemoglobin, lactoperoxidase, myeloperoxidase, cytochrome *c* peroxidase and KatG. The reaction of oxyferrous DHP with H_2O_2 in the presence of as little as one equivalent of TCP cosubstrate also identified DHP Compound II as the first intermediate formed. This result demonstrated that the activation of oxyferrous DHP by trihalophenols can lead directly to a peroxidase-active form of the enzyme without first invoking a ferric resting state. Furthermore, the importance of this observation is also underscored by the *in vivo* role of dehaloperoxidase as an oxygen-transport protein, wherein the globin exists in both the oxy- and deoxyferrous states, and it is reasonable to surmise that the initiation of a peroxidase pathway should not be limited to only one of the two major states of a globin.

Given that there is significant evidence in favor of each of these two hypotheses, it is plausible that more than one mechanism of activation may be present in DHP.

10.3 Structural Relationship of DHP with Peroxidases

Dehaloperoxidase has a globin fold. Although its sequence identity with known globins is low, it has high structural similarity. The spectroscopic observables of DHP are likewise similar to globins. These similarities are so pronounced that there was a concern for many years that DHP was not truly an enzyme, but rather there was an impurity present or some other explanation for the apparent peroxidase activity. The cloning of DHP and careful study of its kinetics have both allayed these concerns. Now the question that arises is how DHP is capable of carrying out peroxidase chemistry, when it has so little structural similarity with peroxidases.

The classic peroxidase structural features have been described in terms of a ''push–pull'' mechanism leading to activation of bound H_2O_2. The push on the proximal side is due to a charge relay that increases the basicity of the ligand to the heme Fe. This in turn supports the oxidation state of the Fe needed for the active species Compound I and II. The pull is due to hydrogen bonding on the distal side. This feature of peroxidases is crucial since the pull is responsible for heterolytic bond cleavage. Globins and peroxidases both have one proximal and one distal histidine. Yet, the function of these amino acids differs significantly in these two classes of proteins. In the following we will discuss the aspects of polarization and conformation of these respective peroxidases in DHP, with reference to the congeners in hemoglobin (myoglobin) and peroxidases. In order to understand these two aspects of peroxidase function, we consider the structural aspects of the proximal and distal sides of the protein in separate sections.

10.3.1 Structural and Electronic Properties of the Proximal Side of the Heme

The ''push'' on the proximal side is facilitated by an increase in the partial negative charge on the proximal histidine due to a charge relay. Goodin *et al.* first proposed the analogy between the Asp-His-Fe charge relay of peroxidases and Asp-His-Ser charge relay in serine proteases.[45] The charge relay in serine proteases consists of a strong hydrogen bond between Asp and the Nδ of His, which leads to partial deprotonation and an increase of the negative charge of the His. The partial negative charge is communicated to the Ser through a second hydrogen bond. The partially deprotonated Ser is a good nucleophile, which is the essential feature of a serine protease. The analogous charge relay in peroxidases increases the charge density on the heme. Thus, the functional aspect of the charge relay is to alter the properties of the proximal histidine so that the heme Fe can support the Fe(IV) oxidation state required for the formation of Compounds I and II. For example, in C*c*P this

relay is formed by Asp235-His175-Fe. Mutation of Asp235 to Asn causes a dramatic reduction in C*c*P enzymatic activity, which correlates with a shift in the frequency of the Fe–His resonance Raman band. In myoglobin, the His93-Ser92 hydrogen bond has been studied in a series of mutants,[46,47] including the S92D variant that would mimic the Asp-His-Fe charge relay.[48] However, it was concluded that this hydrogen bond in myoglobin is responsible for maintaining the protein structure of the proximal heme pocket, but that it does not strongly affect the electronic structure of the heme nor that of the His93 imidazole ring.

DHP lacks the typical peroxidase proximal charge relay. Instead, DHP has a strong hydrogen bond between the backbone carbonyl of L83 and the Nδ-H of the proximal histidine (H89). Can such a hydrogen bond take the place of the Asp-His-Fe charge relay? Although a hydrogen bond of this type can polarize the histidine to an extent, the fact that the backbone carbonyl is neutral limits the possible extent of charge displacement.[49] The effect of the charge relay has been studied using density functional theory (DFT) methods, which show that all neutral hydrogen bonding interactions are qualitatively different from the anionic interaction formed by the Asp in C*c*P.[50] Thus, the charge relay appears to be missing in DHP. Evidence for this can be found in resonance Raman spectroscopy of the proximal His stretching vibration as the value of the wavenumber of the Fe–His band scales with the extent of charge transfer to the Fe. The polarization tends to result in a greater force constant for the Fe–His stretch. The values for typical globins are in the range $\sim 220\,cm^{-1}$ and for peroxidases they are $\sim 242\,cm^{-1}$. DHP is exactly in the middle of these two values at $230\,cm^{-1}$.[51] This observation is consistent with the placement of DHP in an intermediate range having a weak polarization, but nonetheless, one that is outside the range of other globins.

In order to further explore the implications of the proximal hydrogen bonding in DHP, two mutants were constructed to introduce a charge relay into DHP. The M86D and M86E mutants were designed to permit the Asp (D) or Glu (E), respectively, amino acid to interact with the proximal histidine and thereby give rise to a charge relay. However, buried charges are not particularly stable and the X-ray crystal structure of the M86E (PDB 3MYM) DHP mutant revealed that the Glu (E) side chain had rotated out into the solvent in order to avoid being buried inside the protein. Table 10.1 provides a complete list of the PDB structures of DHP. Figure 10.2 shows molecular dynamics (MD) simulations of both the M86D and M86E mutants based on the 3MYN and 3MYM X-ray crystal structures, respectively.[52] These simulations show that M86D can interact with H89 in a dynamic fashion, although neither of the negative amino acids has the same strong effect as the Asp in C*c*P. While the M86E mutant completely failed to give rise to a charge relay, the M86D mutant did have some degree of polarization of the histidine based on a ^{13}C–^{15}N NMR spectrum, resonance Raman spectroscopy, and the reduction potential.[52] In the final analysis, the charge relay in DHP actually reduced the activity of the enzyme. This is believed to be due to the increased

Table 10.1 Crystal structures of DHP deposited into the PDB, arranged from the most recent to the initial structure.[a]

PDB accession no.	Ligand	Mutant	Date of deposition
4JYQ	CO		4/14
4KJT		L100F	2/14
4JAC		T56S	11/13
4GZG	CO		9/13
4KMV	TCP	L100F	9/13
4KMW	TCP	Y34N	9/13
4KN3	TCP	Y34N/S91G	9/13
4HSW		L100F	5/13
4HSX	4BP	L100F	5/13
4FH6	TBP	10% DMSO	3/13
4FH7	TBP	20% methanol	3/13
4ILZ	TBP	10% 2-propanol	3/13
4DWT	CO		2/13
4DWU	CO		2/13
3OK5	4BP	H55D	9/11
3ORD	Xe		9/11
3OJ1		H55D	8/11
3O7N		V59W	7/11
3MOU	Xe		4/11
3MYM		M86E	4/11
3MYN		M86D	4/11
3LB1	4IP		11/10
3LB2	4BP		11/10
3LB3	4CP		11/10
3LB4	4FP		11/10
3K3U		V59W	11/10
3KUN	CN		6/10
3KUO	CN		6/10
3IXF		B isoenzyme	5/10
3DR9		Deoxy form	1/09
2QFK		Ferric form	7/08
2QFN		Oxyferrous form	7/08
1EWA	4IP		5/00
1EW6			5/00

[a]Ligand abbreviations: TCP – 2,4,6-trichlorophenol; TBP – 2,4,6-tribromophenol; 4IP – 4-iodophenol; 4BP – 4-bromophenol; 4CP – 4-chlorophenol; 4FP – 4-fluorophenol.

tendency to form hemichrome (a low-spin globin state seen *en route* to denaturation). The conclusion of the studies of the proximal mutants in DHP was that there is a balance of factors such that there is an optimum polarization of the heme Fe. An increase in polarization enhances reactivity, increases the binding of H_2O_2, and stabilizes the higher oxidation state of the heme Fe. Up to a point the increase in polarization is completely favorable for peroxidase activity since it permits the formation of Compound I. If the extent of polarization is too great, then there will be a greater tendency to form the six-coordinate hemichrome and deactivate the enzyme. Du *et al.* reported that the M86E DHP variant has 9-fold higher activity than wild-type DHP at pH 7 and 1.4-fold higher activity at pH 5.4.[53] However, the activity of

Figure 10.2 Coordinates of the mutated residues M86E and M86D obtained from MD simulations. The bases for the simulations were the X-ray crystal structures PDB 3MYM and PDB 3MYN, respectively.

the mutants is complicated by the fact that k_{cat} and K_m in the Michaelis–Menten kinetic scheme[54] appear to be affected in opposing ways. D'Antonio *et al.* reported that k_{cat} for M86D and M86E are increased by factors of 2.1 and 1.6, respectively, relative to the wild type.[52] This is consistent with the greater negative charge near the Nδ–H atom, which enhances the charge relay effect at the heme Fe. However, the effect on K_m was opposite such that the M86D and M86E increased by factors of ∼9 and ∼3, respectively. Therefore, the catalytic efficiency (k_{cat}/K_m) decreases by a factor of 4.2 and 1.7 relative to wild type for M86D and M86E, respectively. The effect on K_m can be interpreted as a decrease in the on rate for H_2O_2, which is due to the interaction of the distal histidine with the Fe in these mutants observed in the greater tendency for hemichrome formation.

The proximal cavity mutant H89G has been made in DHP.[55] Unlike the case of SWMb where the analogous proximal cavity mutant (H93G) has been made,[56–58] it was not possible to attempt a rescue of function by addition of other ligands to DHP(H89G): this mutant was completely inactive even when imidazole was bound to the heme Fe in the proximal pocket. One can surmise that this is the case since the imidazole would likely be polarized in DHP and this polarization is difficult to replicate in the proximal cavity mutant. For example, the analogous mutant CcP H175G is also inactive.[59,60] Unlike the case of SWMb where the analogous proximal cavity mutant (H93G) has been made, it was not possible to rescue the function of DHP(H89G) by addition of imidazole or other small molecules.[56–58]

10.3.2 Structural and Electronic Properties of the Distal Side of the Heme

Peroxidases employ the distal histidine as a key acid–base catalyst that facilitates heterolytic O–O bond cleavage as described by the Poulos–Kraut mechanism.[61] In all peroxidases, the distal histidine is assisted by an arginine, which is thought to permit stronger hydrogen bonding than would

be possible for histidine alone. In DHP, however, the distal side lacks such an arginine, and moreover the distal histidine has no other near neighbors capable of enhancing the hydrogen bond strength. Instead, we have noted that the distal histidine of DHP is unusually flexible.

Initially, the flexibility of the distal histidine was hypothesized based on the X-ray crystal structures of DHP.[20,21,62–65] A persistent theme in the many structures of DHP in different ligation states is the observation that the histidine, H55, is observed in two conformations, one internal and one external. The internal conformation in the distal pocket is within range to hydrogen bond to ligands bound to the heme Fe. This conformation is shown in Figure 10.2. The external or solvent exposed conformation is partially stabilized by interaction with the propionate side chains. This conformation is also forced by the binding of the inhibitor 4-BP as shown in Figure 10.4. The heme of DHP is ~ 1 more deeply buried in the globin than in other hemoglobins, which means that the propionates are positioned in an appropriate distance to hydrogen bond.[20,21] Our hypothesis states that the balance between the internal and external conformations is determined by the hydrogen bond strength. H_2O can form a strong hydrogen bond to H55, and therefore the population of DHP in the metaquo form has an internal conformation for H55.[62–64] This applies to the oxyferrous and metcyano forms. However, H55 is observed mainly in the external conformation when CO is the ligand.[66] Similar studies have been performed for the distal histidine in SWMb and other myoglobins and hemoglobins. However, in these globins the internal conformation is dominant unless the pH is lowered to pH ~ 4. DHP is unique in that the crystallization conditions of pH 6 are sufficient to drive the histidine to at least 40% into the external conformation.

The flexibility of the distal histidine may well be crucial for peroxidase activity. In a protein that lacks the ancillary arginine and has no other obvious amino acids that can assist in strengthening the hydrogen bonding, it is possible that H55 is susceptible to the conformation of the protein, which in turn may affect substrate and inhibitor binding. The inhibitor effect is easy to understand since it displaces H55 100% into the external conformation. However, substrate binding is more complex and is discussed further later. The flexibility of H55 plays a role in maintaining an open distal pocket, which may be necessary for entry and exit of relatively large substrate molecules. There is a simultaneous effect of substrate binding, which may result in forcing the histidine deeper into the distal pocket, thereby strengthening the hydrogen bond and permitting the acid–base catalysis necessary for the Poulos–Kraut activation of bound peroxide.[67]

One can test the role of the distal histidine by two types of site-directed mutations involving either replacement of the histidine itself (first type) or surrounding amino acids that controls its conformation (second type). First, one can replace the histidine itself with another amino acid. Thus far, the mutants H55D, H55V and H55R have been studied.[55,68] Second, one can alter the amino acids in the vicinity of H55 in order to affect its dynamics. The mutants T56G, T56A, T56S and T56V have been studied in this

category.[69] Turning to the first class of mutations, it is not surprising that the effect of direct mutation of H55 is a drastic decrease in reactivity. The mutant H55V has essentially no reactivity. H55R is decreased by a factor of 5 and H55D is decreased by a factor of ~10. The fact that the charged amino acids are not completely inactive suggests some small degree to which the mutated amino acids may play a role of an acid–base catalyst. H55D has been studied most extensively. In this case, the X-ray crystal structure shows that the aspartate is essentially 100% in the external conformation, which is expected for a negatively charged amino acid. However, molecular dynamics simulations suggest that Asp55 may have some tendency to enter the protein as neutral (protonated) aspartic acid.[68] This form of the amino acid may have a small degree of activity. Thus, even in a much less active amino acid we can observe that the conformational flexibility of the distal ligand is important.

The second category of mutants involves a change in the conformation of the distal histidine. It is at first surprising that the T56 mutants cause an apparent acceleration of the enzymatic rate.[69] However, this greater activity must compete with hemichrome formation, which inactivates DHP. Thus, we see that the same issue discussed for the proximal ligands reappears in the context of the distal amino acids. Pushing the protein towards a greater degree of ligation (distal) or stability of binding (proximal) can accelerate the enzymatic rate, but simultaneously increases the equilibrium for hemichrome formation, which irreversibly deactivates the protein. The evolutionary choice in each case appears to optimize the enzyme by providing a high rate of turnover with minimal hemichrome formation under native conditions.

10.4 Optimal Conditions for DHP Function— Physiological Relevance

There is a pronounced pH effect on substrate turnover that also relates to the optimal pH for substrate turnover. DHP has an unusually low pH for the acid–alkaline transition ($Fe^{3+}-OH_2 \rightarrow Fe^{3+}-{}^-OH + H^+$), which is the p$K_a$ of the metaquo form. In DHP, this pK_a is 8.1.[70] Connected with this observation is the fact that the optimum pH for turnover is $pH = 7.5$ when the criterion used is the greatest concentration of product at the end of an assay. DHP has the unusual feature in that the initial rate accelerates as the pH is lowered below pH 7.5. Figure 10.3 shows that if one were to examine initial rate alone it would appear that the ideal pH is pH 5 or lower. However, this is not a true measure of substrate turnover since there is a deactivation of DHP that competes with turnover, and it is the deactivation that is observed at lower pH rather than substrate turnover. The deactivation can be observed spectroscopically and is linked to the formation of the inactive (or less active) form of DHP called Compound RH. The fact that deactivation is occurring is also evidenced from the kinetic traces, which have a rapid initial onset, and followed by an inactive phase at pH 5. The origins of the branching have

Figure 10.3 Single wavelength kinetics of the oxidative debromination of TBP by DHP as a function of pH. The fits to a single exponential function can be found in ref. 73. **A.** The kinetics at 272 nm. **B.** The kinetics at 316 nm.

been studied in detail using electron paramagnetic resonance (EPR) to understand the pathways for radical formation and transfer among the various tyrosines of DHP.[71,72]

The apparent optimal pH of 7.5 is consistent with the observation of DHP as the most abundant protein in the coelom of *A. ornata*. DHP is an intracellular hemoglobin and, as such, it must function at the pH of cytosol, which is 7.4. Hence, if we compare DHP to the various classes of peroxidases, DHP would appear to be a class I peroxidase. Initially, DHP was studied at low pH by analogy with HRP, which is a secretory peroxidase. Both HRP and DHP are known to oxidize phenols, but the similarity may end there. Secretory peroxidases function at low pH (typically pH 5) because they are secreted into the soil where the pH is typically low. Their function is to degrade various biopolymers so that the components may be ingested by the host that secreted the peroxidase. DHP functions as a multi-functional intracellular peroxidase and as such it follows different criteria. First, it appears that different substrates bind in different modes (discussed later). The inhibitor binds in a specific binding site. If we examine the bromophenols, which are found in the ecosystems where *A. ornata* lives, we can see the interplay of pH, mode of binding and the optimal chemical change.

4-BP (and 4-CP) can dimerize and polymerize upon radical formation.[74] The reason that 4-BP is an inhibitor may be related to this fact. It is possible that this polymerization is detrimental to the organism, and therefore should be suppressed; hence, the binding of 4-BP in an internal binding site. 2,4,6-TBP, on the other hand, is much more toxic, although less abundant.[16] The oxidation of the 2,4,6-TBP yields 2,6-dibromoquinone, which is not a harmful molecule and is even further oxidized. Thus, we can understand that 2,4,6-TBP, unlike 4-BP, is readily oxidized by a peroxidase mechanism. Less is known about 2,4-dibromophenol (2,4-DBP), but we know that it is at a minimum oxidized to a quinone in the same way that 2,4,6-TBP is.

10.5 Inhibition of DHP

The enzymatic mechanism of DHP was perhaps first truly clarified by the realization that certain phenols act as inhibitors rather than substrates. The series of 4-halophenols (4-XPs), 4-iodo-, 4-bromo-, 4-chloro-, 4-fluoro and phenol itself bind in an interior binding pocket in the distal pocket of the globin (denoted (4-IP, 4-BP, 4-CP, 4-FP and P, respectively).[65] Figure 10.4 shows that inhibitors bind in an orientation perpendicular to the heme Fe and slightly offset from the center of the distal pocket so that the heme Fe is partially blocked by the inhibitor.[20,21,65] This partial covering of the heme Fe can be observed by X-ray crystallography, but is also evident in the effect of 4-XP on heme-bound ligands. The binding of 4-XP competes with the binding of ligands to the heme Fe.[65] For example, a water ligand is bound to the ferric heme Fe of the normal resting DHP with approximately 40% of the population, the rest of the population being five-coordinate.[71] These populations can be observed by resonance Raman (rR) spectroscopy. When 4-XPs bind they displace the heme-ligated water, and at sufficiently high 4-XP concentration the heme is 100% five-coordinate. Thus, rR spectroscopy can be used to monitor the binding of the inhibitors. The inhibitors bind with decreasing affinity as the halogen radius decreases. This trend is counter-intuitive if one imagines that the inhibitor must displace amino acids in order to bind in the interior of the DHP. Rather, the trend can be explained by the existence of a cavity inside the protein, which is located precisely where the *para*-halogen atom resides in the bound state. Figure 10.4 shows the binding site for Xe discovered by high pressure Xe X-ray crystallography.


Figure 10.4 Overlay of two X-ray crystal structures showing the internal inhibitor binding site (PDB 3LB2) and the Xe binding site (PDB 3MOU). The Xe binding site is shown by the transparent blue sphere. The bromine atom of 4-BP is shown near the center of the sphere. The hydrophobic amino acids surrounding the Xe/Br binding site are shown. The distal histidine is forced into the solvent-exposed (exterior) conformation.

The Xe binding site is a cavity that is located precisely where the halogen binds in the distal pocket.[75]

Inhibitor binding is quite specific in DHP. However, a range of molecules with similar shapes can also bind in the inhibitor binding site. *para*-Hydroquinone (H_2Q) is one such molecule. H_2Q binds in the inhibitor site and provides information on the role of proton-coupled electron transfer in DHP. H_2Q is converted to BQ only if the distal histidine, H55, is present to act as a proton shuttle. First, H_2Q can be catalytically oxidized to *para*-benzoquinone (BQ) in the presence of H_2O_2. In the absence of H_2O_2, H_2Q reduces the heme to the ferrous state and actively prevents turnover of substrates such as 2,4,6-TCP.[76] While the catalytic oxidation of H_2Q to BQ. While this chemical transformation is not remarkable, the fact that it occurs in the inhibitor binding site is unique. The binding of H_2Q in a site immediately adjacent to the heme Fe means that its oxidation is very rapid. Thus, if H_2Q and the substrate 2,4,6-TCP are both present, the H_2Q reaction dominates and no turnover of TCP is observed until all of the H_2Q is oxidized. This competition gives rise to a kinetic lag phase during which no turnover of 2,4,6-TCP is observed. Once all of the H_2Q has been oxidized there is a sudden onset of 2,4,6-TCP activation.[76]

10.6   The Substrate Binding Conundrum

10.6.1   Evidence for an External Binding Site

The location of the substrate binding site is one of the outstanding unsolved problems in DHP research. Normally, substrate binding in peroxidases occurs at the heme edge (HRP, APX) or at an external docking site that has an electron transfer pathway to the heme (C*c*P). Since the discovery of peroxidase activity in DHP there has been an underlying assumption that DHP follows this model and, indeed, experimental data suggest that DHP has a similar external binding site. For example, flow-EPR has been used to study the formation of a semi-quinone radical in DHP.[77] When compared to HRP, which has an established external binding site near the heme edge,[78] we observe that both of them produce semi-quinone radicals in the flow EPR experiment. This suggests that both enzymes have an external binding site. If DHP follows a well-established pattern observed in heme peroxidases,[79] the external binding site would be on the heme δ-edge labeled in Figure 10.5. An examination of the structure shows that this location has the shortest path for electron transfer from the heme to an externally bound phenol. However, we reiterate that despite extensive studies, there is no direct evidence to date that corroborates this hypothesized binding site.

On the contrary, studies of interactions of phenolic substrates have revealed at least two different internal binding sites (discussed in Section 10.6.2 and 10.6.3). It has already been established that the binding site for 4-BP is inhibitor (Section 10.5) and the evidence to date suggests that the internal substrate binding sites, discussed later, are also inhibitory for peroxidase

Figure 10.5   Stereo view of the distal side of the heme pocket of DHP A (PDB entry 4HF6), showing the position occupied by the substrate, 2,4,6-TBP (shown in magenta), at an internal binding site in the back of the distal pocket. The heme is shown as are amino acid residues L100, F24, V59 and H55 in two conformations (open and closed). The substrate location was determined with the help of the anomalous difference electron density map contoured at 3σ electron density level constructed from the SAD data set at the $K\alpha$ electron transition energy for Br ($\lambda \sim 0.92\,\text{Å}$ Br edge) relative to Fe. Anomalous density is shown in the figure for the three Br atoms and the heme Fe.

function. These sites may be observed because of other functions in DHP (such as the recently characterized peroxygenase function). However, any radical produced by one-electron oxidation would likely react before exiting from the protein, which clearly would inhibit a peroxidase function. We must also consider the fact that DHP is rather rapidly deactivated during the course of the flow-EPR experiment discussed earlier. This can be understood in the context of the radical pathways in the protein involving the five tyrosines in DHP. We conclude that the radical pathways required for an external site may simultaneously result in side reaction(s), which alter the heme and inactivate the enzyme. The exact mechanism is not known, but it is clear that the very conditions that promote peroxidase activity also tend to result in some degree of inactivation by chemical modification of the heme (as discussed in Section 10.7). Members of the C*c*P family appear to have a greater resistance to the kind of inactivation observed in DHP, perhaps because of their evolutionary specialization. Despite the data showing that an external binding site exists, it is not possible to exclude an internal binding site. Indeed, the observation of an internal site for 4-BP has been one of the hallmarks of the unique role played by DHP since its discovery as a peroxidase in 1996.

10.6.2   Evidence for TBP Binding Sites in the Distal Pocket

It is rather easy to soak the inhibitors 4-IP, 4-BP, 4-CP and 4-FP into a crystal of DHP and to obtain a crystal structure.[20,21,65] However, when the exact

same experiment is attempted with 2,4,6-TCP, no substrate molecules are observed in the crystal. It was determined that a major reason for this is the relatively low solubility of 2,4,6-TCP. This is even more of a problem for 2,4,6-TBP. One can overcome this problem using non-aqueous solvents. Use of 10% methanol, 2-propanol or dimethyl sulfoxide increases the solubility of 2,4,6-TCP and 2,4,6-TBP sufficiently that one can observe a small amount of electron density in the distal pocket (PDB 4FH6, 4ILZ, and 4FH7).[76] However, the X-ray crystal structure (PDB 4FH6) shown in Figure 10.5 indicates that the substrate binds internally. Table 10.1 lists the various inhibitors and substrates that have been observed in X-ray crystal structures of DHP. Internal binding of the substrate is difficult to rationalize with the observed kinetics from the flow-EPR experiment, or in fact, any peroxidase mechanism.[77] The peroxidase mechanism commonly involves one-electron oxidation to form a radical followed by disproportionation of the radicals to form one molecule of reactant and one of the oxidized intermediate that will convert to the product upon reaction with H_2O.

10.6.3   Evidence for TCP Binding Sites in the Distal Pocket

Classical peroxidases oxidize many small aromatic ligands predominantly at the δ-edge of the heme, as has been reviewed by Gumiero *et al*.[80] Although HRP and other peroxidases catalyze the dehalogenation of phenols, no information about their halophenol binding site(s) is available. To establish if the δ-edge oxidation takes place in DHP and Mb dehaloperoxidative activity, a number of crystal soaking experiments with TCP and phenol have been carried out. In addition to wt-DHP, several mutants and very high concentration of TCP were used. This approach yielded a number of high occupancy DHP complexes for which structures were determined and are available in the Protein Data Bank: T34N•TCP, PDB 4KMW; T34N/S91G•TCP, PDB 4KN3; L100F•TCP, PDB 4KMV,[81] and a myoglobin complex Mb•phenol, PDB 3U3E.[82] Different modes of binding were observed in the two protomers present in an asymmetric part of the crystallographic unit cell consistent with a high degree of flexibility of the distal pocket in DHP. There is no correlation between the mutant peroxidase activity and crystal binding, which indicates that the observed complexes are not catalytic sites for the peroxidase function of DHP, but may be responsible for substrate inhibition observed at high TBP and TCP concentration. An internal binding site at the α heme edge, which was seen with ∼0.1 occupancy in the DHP•TBP complex (PDB 4FH6) based on anomalous diffraction, has also been observed with an occupancy of ∼0.5 in one of the two subunits of the crystallographic dimer of both Y34N/S91G•TCP (PDB 4kn3) and L100F•TCP (PDB 4KMV). The higher TCP occupancy allowed us to determine that in each case the heme was in the aquomet state while the original crystals used for soaking were in the oxyferrous state. Thus, the TCP presence in soaking solutions led to heme oxidation, apparently by O_2 since H_2O_2 was not present. It may be speculated that the internal binding mode, while not catalytic, could be

involved in the process of DHP oxidation/activation in the presence of halophenols. The TCP binding site near the α-heme edge is clearly not consistent with peroxidase function, so that the one-electron oxidized substrate can diffuse into solution. The α-heme-edge site may be involved in other functions of DHP,[31] or may even be an inhibitor binding site similar to the 4-BP binding site discussed earlier.

A second internal TCP binding site was observed at the heme β-edge with full occupancy in both protomers of Y34N•TCP (PDB 4KMW). We have recently called this the β-site because it is closer to the heme β-edge. It has a large overlap with the known inhibitor binding site as is evident in Figure 10.7. In Y34N/S91G•TCP, the situation is more complex. One protomer shows TCP bound in the β-site with full occupancy and the other shows TCP disordered between the α- and β-sites with equal occupancies. These two binding sites partially overlap and cannot be simultaneously occupied. Structural changes induced in DHP by TCP binding in the β-site can be observed because of the full occupancy and are shown in Figure 10.6.

The distal histidine binding site has similarity with the 4-BP site in that the distal histidine is forced into the solvent-exposed (open) conformation and the TCP molecule blocks the heme Fe. In addition, chlorine atom Cl4 partially overlaps with the modeled position of the active oxygen atom of Compound I, although there is no contact between TCP and the heme Fe.


Figure 10.6 Stereo view of the least squares superposition of Y34N complexes with oxygen (in blue) and TCP (in atom colors). The TCP molecule pushes the heme down leading to its tilting by 6° and the movement of its edge by 0.8 Å. The Cl atom at position 4 is not in contact with the heme Fe; its position is very close to that of the distal atom of the dioxygen molecule. The TCP molecule forms contacts in a 3.1 to 3.5 Å range with the heme atoms: Cl2 atom with C1D and the D propionate, C3 with ND, C1D, C2D and C3D, Cl4 with NC, C4C and ND. Note that the PDB heme nomenclature is not the same as used here, δ-edge atoms have the letter "B" in their names.

There are numerous contacts shorter than 3.5 Å between the Cl2, C3 and Cl4 atoms of TCP and the heme atoms.

The concentrations of trihalophenols needed to observe binding in crystals are much higher than the values of K_m measured by kinetics. This is likely due to the fact that for catalysis the substrate binds to Compound I, not to the ferric enzyme and apparently this intermediate has much higher affinity for phenolic substrates. The same conclusion was reached for the classical myoglobin from sperm whales in the study of dehaloperoxidase reaction inhibition by phenol.[82] Even though the internal TCP binding site perpendicular to the heme observed in DHP is inhibitory, it is not unlikely that the productive binding to Compound I or Compound II is somewhat structurally similar. First, the oxygen atom bound to Fe(IV) is strongly polarized and thus a poor hydrogen bond acceptor. It is also further from the distal histidine since the Fe–O bond is shorter. Thus the distal histidine (His55) likely is out of the distal cavity in the intermediates and can bind the hydroxyl of TCP like in the inhibitory complex. This hydroxyl forms another hydrogen bond with the hydroxyl of Tyr38. The Y38N variant of DHP has a 13-fold higher activity which can be explained by the proposed model. The absence of the hydrogen bond in Y38N reduces the electron density on the TCP hydroxyl and should facilitate electron transfer to the heme, likely through Cl4-heme contacts. These studies suggest that the emerging consensus about the role of the heme δ edge in peroxidases may apply to DHP.

There is always a concern that the binding observed is due to an artifact of the conditions (crystalline form and the use of non-aqueous solvents). Recent data demonstrating the multi-functional nature of DHP suggest that these sites may relate to non-peroxidase functions. They may also be inhibitor sites, since substrate inhibition is observed in DHP. Therefore, at this time we have no evidence that any of the binding sites is an artifact and significant evidence linking each of the sites to some aspect of known DHP function. These structures do not resolve the most important issue for peroxidase function since none of the X-ray crystallographic studies have revealed any binding near the δ-heme edge. The radical mechanism for oxidation of TCP shown by flow-EPR studies and radical trapping clearly show that there must be a significant component of external binding. Other methods (*e.g.* NMR) will likely be needed in the search for an external (δ-heme edge) binding site consistent with peroxidase function. However, the X-ray crystal structure studies have revealed unique features of the hemoglobin-peroxidase that suggest it is a multi-functional enzyme. In this review we have focused only the peroxidase function. Therefore, we conclude that the internal binding sites for both 4-BP and TCP are most consistent with inhibition with regard to the peroxidase mechanism.

Figure 10.7 shows a superposition of the known internal binding sites in DHP and the binding sites in HRP and C*c*P. One can see that the benzhydroxamic acid and isoniazid binding sites are not nearly as deeply buried as any of the internal sites in DHP. The internal binding of 4-XPs and TXPs depends on the flexibility of the distal histidine, H55, which permits the

Figure 10.7 Substrate binding sites in DHP. Protein is shown in atom colors, the heme in brown, TCP bound in an internal site (at α-edge) is in orange, TCP in a second internal site (closest to the β-edge) is in cyan (from PDB 4KN3), and 4-CP bound in a similar site nearest to the β-edge is in violet (from PDB 3LB3). The proximal (H98) and the distal (H55) histidines are marked. Also, the relative positions of two substrates for peroxidases are shown: benzhydroxamic acid from the complex with HRP in red (from PDB 2ATJ) and isoniazid from the complex with cytochrome *c* peroxidase (CcP), in purple. This figure shows that all of the crystallographically observed binding sites in DHP are in the distal cavity.

distal pocket to open sufficiently for both inhibitors and substrate to enter and exit.

10.6.4 Relationship Between Internal Inhibitor Binding and Heme Stability

One intriguing observation with regard to these internally bound structures is that the two highest resolution structures of DHP have 4-BP bound internally in the distal pocket. We can compare the resolution of the series of 4-halophenols bound in the distal pocket DHP(4-FP), DHP(4-CP), DHP(4-BP) and DHP(4-IP), which have resolutions of 1.56, 1.85, 1.06 and 1.76 (PDB 3LB4, 3LB3, 3LB2 and 3LB1), respectively (see Table 10.1).[65] The L100F(4-BP) mutant (PDB 4HSX) has a resolution of 1.12 while the resolution of the L100F protein with no ligand in the distal pocket (PDB 4HSW) is 1.22 .[83] The substantial increase in resolution when 4-BP binds led to the hypothesis that the specific fit of 4-BP stabilizes the globin structure. This specificity is explained, in part, by the Xe-binding cavity that is precisely where the Br atom of 4-BP binds. A corollary to this would be that the heme itself would be stabilized by the binding of 4-BP since protein denaturation in a globin is concomitant with heme loss. This hypothesis was tested using denaturants

in a heme stability study. The holoprotein denatures as the heme is lost so that this is also a protein stability study that others have developed in the context of myoglobin and its mutants.[84,85] Indeed, the heme in DHP is less stable than most globins. It appears that DHP B is less stable than DHP A, which leads to the hypothesis that the increased flexibility of the distal pocket leads to both greater reactivity and lower stability towards heme binding.[86] The relationship of inhibitor binding and heme stability is complicated by the fact that 4-BP also acts as a denaturant at concentrations >3 mM and then synergistically with either urea of guanidinium hydrochloride at somewhat lower concentration. However, at modest concentration [4-BP] <1 mM, there is an opposite effect in which 4-BP stabilizes the heme against urea denaturation. These effects and the heme loss can be compared with experiments done on other peroxidases.

10.7   Deactivation of DHP

In the previous discussion of DHP activity there has been an undercurrent of another important theme in DHP: the inactivation of the protein. All heme proteins are sensitive to degradation by H_2O_2, but DHP appears to be more sensitive than members of the CcP family. In fact, DHP is more sensitive than typical globins such as SWMb. Of course, SWMb is a very poor peroxidase to begin with, but the point is that there is relatively little deactivation of SWMb compared to DHP. We can summarize the observations as a hypothesis for the inactivation of globin peroxidases: the higher the turnover of the peroxidase, the greater the rate of inactivation. This hypothesis has a corollary in the pH dependence of the kinetics. We have already seen that as the pH is lowered the apparent initial rate increases, but the final concentration of product decreases.[87] This is because the competing reaction leading to alteration of the heme also accelerates as the pH is lowered. Thus, pH lowering has a favorable effect on the kinetics, but that effect does not make DHP a better enzyme.

   The hypothesis that the higher the turnover of the peroxidase leads to a greater rate of inactivation has been explored in DHP using a series of Tyr→ Phe variants. DHP A has five tyrosines (Y16, Y28, Y34, Y38, and Y107), while DHP B has one fewer tyrosine since position 34 is naturally an asparagine in this isoform. The location of the radical in DHP A is pH-dependent, with the dominant radical attributed to Tyr34 (pH 7) and the secondary to Tyr38 (pH 5), with radical character forming on Tyr28 when both of these residues are replaced with phenylalanines. In DHP B, the radical is initially formed on Tyr38 due to the natural substitution of tyrosine to an asparagine at position 34 in the B isoform; radical character on Tyr28 is also observed at longer times. Mutagenesis studies also demonstrated that replacement of the tyrosines at both positions 34 and 38 led to Compound I being observed on the stopped-flow timescale. While the Compound I forming variants all exhibited vastly greater peroxidase activity (∼8–12 fold greater) when compared to the native DHP isoforms, they were also nearly two orders of

magnitude more rapidly inactivated by heme bleaching in the absence of substrate. This led to the conclusion that the formation of tyrosyl radicals in Compound ES is a protective mechanism against heme bleaching caused by Compound I formation in the absence of substrate. Essentially, DHP employs sacrificial substrates in the form of tyrosines that prevent irreversible heme bleaching by leading to Compound RH formation in the wild-type isoforms.

These observations beg the question: what is the structure of Compound RH? This has been a vexing problem since Compound RH is formed under conditions where there are usually a mixture of products and protein in various states of deactivation. It is known that the heme in Compound RH has a Soret band at 411 nm, which is a distinguishing feature (WT metaquo DHP has $\lambda_{max} = 407$ nm, oxyferrous DHP has $\lambda_{max} = 418$ nm, and Compound II has $\lambda_{max} = 420$ nm).[33] Thus, we can observe formation of Compound RH in a stopped-flow or benchtop mixing experiment using UV-vis spectroscopy. Using HPLC, a heme crosslinked to the protein has been observed under these conditions,[71] although tryptic digests have yet to be performed to conclusively determine the amino acid residues involved. However, attempts to obtain resonance Raman spectra or X-ray crystal structures of the H_2O_2 treated form of DHP have not resulted in any definitive result. Thus, we have no conclusive information. However, it is reasonable to assume that Compound RH is an end point for the tyrosine radicals formed during turnover in the absence of substrate. When substrate is present, the tyrosyl radicals are used in the oxidation of trihalophenol and less RH is formed. This follows from the fact that the substrate can be oxidized instead of the protein/heme and thus the substrate in essence plays a protective role *vis-a-vis* formation of Compound RH. Many of these same issues exist in other peroxidases, but those peroxidases are apparently less sensitive to degradation and therefore, this has not been as crucial an issue. However, one may surmise that certain crosslinks found to occur naturally in peroxidases may be part of a protective role that the protein can play.

10.8 The Multi-functional Nature of DHP—Beyond Pure Peroxidase Activity

Given that Compound I has been implicated in the mechanisms of other hemoproteins of vastly different enzymatic functions (*i.e.*, cytochrome *c* oxidase, cytochrome P450 monooxygenase, human indoleamine 2,3-dioxygenase, the fungal peroxygenase *Aae*APO, horseradish peroxidase, and prostaglandin endoperoxide synthase), there exists the possibility that the hemoglobin-dehaloperoxidases exhibit additional enzymatic activities. One such activity, peroxygenase, has recently been identified in DHP using haloindole substrates.[31] In that study, the evidence strongly suggests that DHP is capable of peroxygenase activity that is similar to that observed for the peroxide shunt pathways of both P450 monooxygenase and indoleamine

2,3-dioxygenase. In this mechanism, hydrogen peroxide binds to the heme Fe and forms the high valent ferryl intermediate, followed by oxygen atom transfer to the substrate. This peroxygenase activity is observed to some extent in other heme proteins, but it is efficient in DHP and it appears specific for haloindoles that are also known to exist in the benthic ecosystems within which *A. ornata* inhabits. Moreover, the peroxygenase activity was observed to be initiated from either the ferric or oxyferrous states, with the enzyme returning to the oxyferrous state upon completion of its activity due to an unusual product-driven oxidase reaction that ultimately forms indigo derivatives as products. The fact that the peroxygenase activity is initiated from, and returns to, the oxyferrous state is likely related to the primary function of DHP of serving as an oxygen transport protein, yet also highlights the plasticity of the DHP active site for supporting multiple enzymatic functions.

10.9   Conclusion

DHP has proven to be a true peroxidase enzyme. DHP introduces a new paradigm for peroxidases since it provides a means to begin to explore the evolutionary origins of the peroxidase family. Since globins have the longest known genealogy that extends back 1.8 billion years, the observation of peroxidase activity in a globin gives us a glimpse of how peroxidase activity may have originally come into being. We do not mean to suggest that DHP is an evolutionary remnant, but rather that DHP serves as a model for our thinking about how protein function has evolved. In general, intracellular peroxidase activity that generates reactive oxygen species is thought to be unfavorable. However when environmental pressure to detoxify brominated compounds in marine ecosystems appeared with the emergence of species producing these toxins, a relatively inefficient, substrate-activated peroxidase was needed, thus the higher globin peroxidase activity observed in DHP evolved. The disadvantage that DHP is inactivated rather readily must be weighed against the potential toxicity of certain of the brominated compounds that have been found in benthic ecosystems. The diverse range of functions exhibited by DHP highlights the versatility of this heme protein. The trade-off in being a more versatile enzyme is that DHP exhibits catalytic efficiencies below its mono-functional counterparts, albeit far greater than what is noted as side reactivity in other systems. This increased versatility at the expense of high catalytic efficiency is likely attributable to the nature of the DHP active site in that it lacks the additional structural features normally observed in more specialized systems that tune the protein towards one specific discrete function. Thus, DHP provides a platform for probing in detail how Nature evolved structure–function relationships in ancestral multi-functional systems of competent catalytic activity from lower organisms to achieve the complexity necessary for specialization of function and increased activity observed in the mono-functional systems of higher organisms.

Acknowledgements

References

1. R. Hardison, *J. Exp. Biol.*, 1998, **201**, 1099.
2. Y. P. Chen, S. A. Woodin, D. E. Lincoln and C. R. Lovell, *J. Biol. Chem.*, 1996, **271**, 4609.
3. P. George and D. H. Irvine, *J. Phys. Chem.*, 1959, **63**, 415.
4. P. George and D. H. Irvine, *Biochem. J.*, 1953, **53**, R25.
5. P. George and D. H. Irvine, *Nature*, 1951, **168**, 164.
6. D. Keilin and E. F. Hartree, *Nature*, 1950, **166**, 513.
7. H.-P. Hersleth, Y.-W. Hsiao, U. Ryde, C. H. Görbitz and K. K. Andersson, *Chem. Biodiversity*, 2008, **5**, 2067.
8. C. Wang, L. L. Lovelace, S. Sun, J. H. Dawson and L. Lebioda, *Acta Cryst.*, 2014, **D70**, 2833.
9. R. Silaghi-Dumitrescu, B. J. Reeder, P. Nicholls, C. E. Cooper and M. T. Wilson, *Biochem. J.*, 2007, **403**, 391.
10. L. L. Wan, M. B. Twitchett, L. D. Eltis, A. G. Mauk and M. Smith, *Proc. Natl. Acad. Sci. U. S. A.*, 1998, **95**, 12825.
11. S. Ozaki, I. Hara, T. Matsui and Y. Watanabe, *Biochemistry*, 2001, **40**, 1044.
12. T. Matsui, S.-i. Ozaki and Y. Watanabe, *J. Biol. Chem.*, 1997, **272**, 32735.
13. A. Kapralov, Vlasova, II, W. Feng, A. Maeda, K. Walson, V. A. Tyurin, Z. Huang, R. K. Aneja, J. Carcillo, H. Bayir and V. E. Kagan, *J. Biol. Chem.*, 2009, **284**, 30395.
14. K. T. Fielman, S. A. Woodin and D. E. Lincoln, *Environ. Toxicol. Chem.*, 2001, **20**, 738.
15. K. T. Fielman, S. A. Woodin, M. D. Walla and D. E. Lincoln, *Mar. Ecol.: Prog. Ser.*, 1999, **181**, 1.
16. D. E. Lincoln, K. T. Fielman, R. L. Marinelli and S. A. Woodin, *Biochem. Syst. Ecol.*, 2005, **33**, 559.
17. S. A. Woodin, S. M. Lindsay and D. E. Lincoln, *Mar. Ecol.: Prog. Ser.*, 1997, **157**, 303.
18. Y. P. Chen, D. E. Lincoln, S. A. Woodin and C. R. Lovell, *J. Biol. Chem.*, 1991, **266**, 23909.
19. R. E. Weber, C. Mangum, H. Steinman, C. Bonaventura, B. Sullivan and J. Bonaventura, *Comp. Biochem. Physiol. A Comp. Physiol.*, 1977, **56**, 179.
20. L. Lebioda, M. W. LaCount, E. Zhang, Y. P. Chen, K. Han, M. M. Whitton, D. E. Lincoln and S. A. Woodin, *Nature*, 1999, **401**, 445.
21. M. W. LaCount, E. L. Zhang, Y. P. Chen, K. P. Han, M. M. Whitton, D. E. Lincoln, S. A. Woodin and L. Lebioda, *J. Biol. Chem.*, 2000, **275**, 18712.

22. K. Han, S. A. Woodin, D. E. Lincoln, K. T. Fielman and B. Ely, *Mar. Biotechnol.*, 2001, **3**, 287.

23. D. E. Lincoln, K. T. Fielman, R. L. Marinelli and S. A. Woodin, *Biochem. Syst. Ecol.*, 2005, **33**, 559.

24. E. Zhang, Y. P. Chen, M. P. Roach, D. E. Lincoln, C. R. Lovell, S. A. Woodin, J. H. Dawson and L. Lebioda, *Acta Cryst.*, 1996, **D52**, 1191.

25. J. D'Antonio, E. L. D'Antonio, M. K. Thompson, E. F. Bowden, S. Franzen, T. Smirnova and R. A. Ghiladi, *Biochemistry*, 2010, **49**, 6600.

26. V. de Serrano, J. D'Antonio, S. Franzen and R. A. Ghiladi, *Acta Cryst.*, 2010, **D66**, 529.

27. S. Sun, M. Sono, C. Wang, J. Du, L. Lebioda and J. H. Dawson, *Arch. Biochem. Biophys.*, 2014, **545**, 108.

28. E. Chiancone, G. Ferruzzi, C. Bonaventura and J. Bonaventura, *Biochim. Biophys. Acta*, 1981, **670**, 84.

29. E. Chiancone, M. Brenowitz, F. Ascoli, C. Bonaventura and J. Bonaventura, *Biochim. Biophys. Acta*, 1980, **623**, 146.

30. M. K. Thompson, S. Franzen, M. F. Davis, R. C. Oliver and J. K. Krueger, *J. Phys. Chem. B*, 2011, **115**, 4266.

31. D. Barrios, J. D'Antonio, N. McCombs, J. Zhao, S. Franzen, A. C. Schmidt, L. Sombers and R. A. Ghiladi, *J. Am. Chem. Soc.*, 2014, **136**, 7914.

32. F. P. Nicoletti, M. K. Thompson, S. Franzen and G. Smulevich, *JBIC, J. Biol. Inorg. Chem.*, 2011, **16**, 611.

33. J. Feducia, R. A. Dumarieh, L. B. G. Gilvey, T. Smirnova, S. Franzen and R. A. Ghiladi, *Biochemistry*, 2009, **48**, 995.

34. R. P. Ferrari, E. Laurenti and F. Trotta, *JBIC, J. Biol. Inorg. Chem.*, 1999, **4**, 232.

35. R. L. Osborne, G. M. Raner, L. P. Hager and J. H. Dawson, *J. Am. Chem. Soc.*, 2006, **128**, 1036.

36. J. Belyea, L. B. Gilvey, M. F. Davis, M. Godek, T. L. Sit, S. A. Lommel and S. Franzen, *Biochemistry*, 2005, **44**, 15637.

37. R. L. Osborne, M. K. Coggins, M. Walla and J. H. Dawson, *Biochemistry*, 2007, **46**, 9823.

38. V. de Serrano, J. D'Antonio, S. Franzen and R. A. Ghiladi, *Acta Cryst.*, 2010, **D66**, 529.

39. R. L. Osborne, L. O. Taylor, K. P. Han, B. Ely and J. H. Dawson, *Biochem. Biophys. Res. Commun.*, 2004, **324**, 1194.

40. E. L. D'Antonio, E. F. Bowden and S. Franzen, *J. Electroanal. Chem.*, 2012, **668**, 37.

41. S. Franzen, M. K. Thompson and R. A. Ghiladi, *Biochim. Biophys. Acta*, 2012, **1824**, 578.

42. J. D'Antonio and R. A. Ghiladi, *Biochemistry*, 2011, **50**, 5999.

43. J. Du, M. Sono and J. H. Dawson, *Biochemistry*, 2010, **49**, 6064.

44. S. Sun, M. Sono, J. Du and J. H. Dawson, *Biochemistry*, 2014, **53**, 4956.

45. D. B. Goodin and D. E. McRee, *Biochemistry*, 1993, **32**, 3313.

46. E. S. Peterson, J. M. Friedman, E. Y. T. Chien and S. G. Sligar, *Biochemistry*, 1998, **37**, 12301.

47. S. J. Smerdon, S. Krzywda, A. J. Wilkinson, R. E. Brantley, T. E. Carver, M. S. Hargrove and J. S. Olson, *Biochemistry*, 1993, **32**, 5132.

48. Y. Shiro, T. Iizuka, K. Marubayashi, T. Ogura, T. Kitagawa, S. Balasubramanian and S. G. Boxer, *Biochemistry*, 1994, **33**, 14986.

49. M. M. Fitzgerald, M. L. Trester, G. M. Jensen, D. E. McRee and D. B. Goodin, *Protein Sci.*, 1995, **4**, 1844.

50. S. Franzen, *J. Am. Chem. Soc.*, 2001, **123**, 12578.

51. S. Franzen, M. P. Roach, Y. P. Chen, R. B. Dyer, W. H. Woodruff and J. H. Dawson, *J. Am. Chem. Soc.*, 1998, **120**, 4658.

52. E. L. D'Antonio, J. D'Antonio, V. de Serrano, H. Gracz, M. K. Thompson, R. A. Ghiladi, E. F. Bowden and S. Franzen, *Biochemistry*, 2011, **50**, 9664.

53. J. Du, X. Huang, S. Sun, C. Wang, L. Lebioda and J. H. Dawson, *Biochemistry*, 2011, **50**, 8172.

54. H. A. Ma, M. K. Thompson, J. Gaff and S. Franzen, *J. Phys. Chem. B*, 2010, **114**, 13823.

55. S. Franzen, C. Chaudhary, J. Belyea, L. Gilvey, M. F. Davis, T. L. Sit and S. A. Lommel, *Biochemistry*, 2006, **45**, 9085.

56. S. Franzen, D. A. Brown, E. Petersen, J. Friedman, M. R. Thomas and S. G. Boxer, *Eur. J. Biochem.*, 2002, **269**, 4879.

57. M. Negrerie, S. G. Kruglik, J. C. Lambry, M. H. Vos, J. L. Martin and S. Franzen, *J. Biol. Chem.*, 2006, **281**, 10389.

58. A. E. Pond, M. P. Roach, M. R. Thomas, S. G. Boxer and J. H. Dawson, *Inorg. Chem.*, 2000, **39**, 6061.

59. D. E. McRee, G. M. Jensen, M. M. Fitzgerald, H. A. Siegel and D. B. Goodin, *Proc. Natl. Acad. Sci. U. S. A.*, 1994, **91**, 12847.

60. J. Sun, M. M. Fitzgerald, D. B. Goodin and T. M. Loehr, *J. Am. Chem. Soc.*, 1997, **119**, 2064.

61. T. L. Poulos and J. Kraut, *J. Biol. Chem.*, 1980, **255**, 10322.

62. Z. Chen, V. de Serrano, L. Betts and S. Franzen, *Acta Cryst.*, 2009, **D65**, 34.

63. V. de Serrano, Z. X. Chen, M. F. Davis and S. Franzen, *Acta Cryst.*, 2007, **D63**, 1094.

64. V. S. de Serrano, M. F. Davis, J. F. Gaff, Q. Zhang, Z. Chen, E. L. D'Antonio, E. F. Bowden, R. Rose and S. Franzen, *Acta Cryst.*, 2010, **D66**, 770.

65. M. K. Thompson, M. F. Davis, V. de Serrano, F. P. Nicoletti, B. D. Howes, G. Smulevich and S. Franzen, *Biophys. J.*, 2010, **99**, 1586.

66. J. J. Zhao, V. de Serrano and S. Franzen, *Biochemistry*, 2014, **53**, 2474.

67. T. L. Poulos and J. Kraut, *J. Biol. Chem.*, 1980, **255**, 8199.

68. J. J. Zhao, V. de Serrano, R. Dumarieh, M. Thompson, R. A. Ghiladi and S. Franzen, *J. Phys. Chem. B*, 2012, **116**, 12065.

69. S. Jiang, I. Wright, P. Swartz and S. Franzen, *Biochim. Biophys. Acta, Proteins Proteomics*, 2013, **1834**, 2020.

70. K. Nienhaus, P. Deng, J. Belyea, S. Franzen and G. U. Nienhaus, *J. Phys. Chem. B*, 2006, **110**, 13264.

71. M. K. Thompson, S. Franzen, R. A. Ghiladi, B. J. Reeder and D. A. Svistunenko, *J. Am. Chem. Soc.*, 2010, **132**, 17501.

72. R. Dumarieh, J. D'Antonio, A. Deliz-Liang, T. Smirnova, D. A. Svistunenko and R. A. Ghiladi, *J. Biol. Chem.*, 2013, **288**, 33470.
73. S. Franzen, L. B. Gilvey and J. L. Belyea, *Biochim. Biophys. Acta, Proteins Proteomics*, 2007, **1774**, 121.
74. R. L. Osborne, M. K. Coggins, G. M. Raner, M. Walla and J. H. Dawson, *Biochemistry*, 2009, **48**, 4231.
75. V. S. de Serrano and S. Franzen, *Peptide Sci.*, 2012, **98**, 27.
76. J. Zhao, J. J. Zhao and S. Franzen, *J. Phys. Chem. B*, 2013, **117**, 14615.
77. B. E. Sturgeon, B. J. Battenburg, B. J. Lyon and S. Franzen, *Chem. Res. Toxicol.*, 2011, **24**, 1862.
78. A. Henriksen, D. J. Schuller, K. Meno, K. G. Welinder, A. T. Smith and M. Gajhede, *Biochemistry*, 1998, **37**, 8054.
79. M. A. Ator, S. K. David and P. R. Ortiz de Montellano, *J. Biol. Chem.*, 1987, **262**, 14954.
80. A. Gumiero, C. L. Metcalfe, A. R. Pearson, E. L. Raven and P. C. E. Moody, *J. Biol. Chem.*, 2011, **286**, 1260.
81. C. Wang, L. L. Lovelace, S. Sun, J. H. Dawson and L. Lebioda, *Biochemistry*, 2013, **52**, 6203.
82. X. Huang, C. Wang, L. R. Celeste, L. L. Lovelace, S. Sun, J. H. Dawson and L. Lebioda, *Acta Cryst.*, 2012, **F68**, 1465.
83. A. Plummer, M. K. Thompson and S. Franzen, *Biochemistry*, 2013, **52**, 2218.
84. M. S. Hargrove, A. J. Wilkinson and J. S. Olson, *Biochemistry*, 1996, **35**, 11300.
85. M. S. Hargrove, S. Krzywda, A. J. Wilkinson, Y. Dou, M. Ikeda-Saito and J. S. Olson, *Biochemistry*, 1994, **33**, 11767.
86. P. Le, J. Zhao and S. Franzen, *Biochemistry*, 2014, **53**, 6863.
87. S. Franzen, L. B. Gilvey and J. Belyea, *Biochim. Biophys. Acta, Protein. Struct. Mol. Enzymol.*, 2007, **1775**, 121.